<DOC>
	<DOC>NCT02580591</DOC>
	<brief_summary>The study will investigate the efficacy, safety, tolerability and PK of 3 doses of empagliflozin compared with placebo over 26 weeks in 960 patients with type 1 diabetes mellitus as adjunctive therapy to insulin</brief_summary>
	<brief_title>Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criteria: Signed and dated written informed consent Male or female patient receiving insulin for the treatment of documented diagnosis of type 1 diabetes mellitus (T1DM) &gt; 1 year Cpeptide value of &lt; 0.7 ng/mL Use of Multiple Daily Injections (MDI) of insulin or insulin pump user with total daily insulin &gt;= 0.3 and &lt;= 1.5 U/kg Glycated haemoglobin (HbA1c) &gt;= 7.5% and &lt;= 10.0% Good understanding of T1DM Age &gt;= 18 years Body Mass Index (BMI) &gt;= 18.5 kg/m2 Estimated glomerular filtration rate &gt;= 30 mL/min/1.73 m2 Women of childbearing potential must use highly effective methods of birth control Compliance with trial medication administration between 80% and 120% during placebo runin period Further inclusion criteria apply Exclusion criteria: History of type 2 diabetes mellitus, maturity onset diabetes of the young (MODY), pancreatic surgery or chronic pancreatitis Pancreas, pancreatic islet cells or renal transplant recipient T1DM treatment with any other antihyperglycaemic drug except subcutaneous basal and bolus insulin within last 3 months Occurrence of severe hypoglycaemia within last 3 months and until randomisation Occurence of diabetic ketoacidosis within 3 months prior to Visit 1 and until Visit 6 Irregular sleep/wake cycle Acute coronary syndrome, stroke or TIA within last 3 months Severe gastroparesis Brittle diabetes Liver disease Eating disorders Treatment with antiobesity drugs, weightloss surgery or aggressive diet regimen Treatment with systemic corticosteroids Change in dose of thyroid hormones within last 6 weeks and until randomisation Cancer or treatment for cancer in the last five years Blood dyscrasias or any disorders causing haemolysis or unstable red blood cells Women who are pregnant, nursing, or who plan to become pregnant whilst in the trial Alcohol or drug abuse Intake of an investigational drug in another trial within last 30 days Further exclusion criteria apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>